NeoGenomics, Inc.NEONASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank64
3Y CAGR-21.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-21.1%/yr
Annual compound
Percentile
P64
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 18.99% |
| 2024 | 14.10% |
| 2023 | -9.95% |
| 2022 | 38.65% |
| 2021 | 165.80% |
| 2020 | -3.04% |
| 2019 | 182.81% |
| 2018 | -17.46% |
| 2017 | -21.79% |
| 2016 | 10.74% |